A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " AntiCancer Japan

AntiCancer Japan

Table of Contents

AntiCancer Japan is a contract research organization (CRO) specializing in non-clinical studies in oncology. By utilizing proprietary tumor models and bioluminescence technologies, they offer flexible efficacy evaluations in non-GLP environments. Their strength is in pharmaceuticals and regenerative medicine products.

Features of AntiCancer Japan’s Non-Clinical Study Services

Extensive Collection of Unique Tumor Models Specialized in Oncology

AntiCancer Japan focuses exclusively on oncology-related non-clinical research. They offer a wide range of tumor models, including CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, to provide practical data for therapeutic drug candidates.

In addition, the company can accommodate flexible design and advanced analytical items, such as luminescence and fluorescence imaging–based monitoring, combination therapy, and tumor relapse models. They have the platform that satisfies the quality and timely execution that are essential to oncology drug development.

Flexible Study Design for Exploratory Research (non-GLP)

Their research facilities are non-GLP (not compliant with Good Laboratory Practice). They have greater flexibility in exploratory research and early-stage screening.

In the early phases of drug development, flexibility and speed are often critical. AntiCancer Japan conducts all of their studies in-house. This enables direct communication with researchers to design customized studies and models tailored to specific needs. Their strength lies on the ability to conduct trials and exploratory studies that may be difficult in GLP-compliant environments, especially during the initial developmental stage.

Interactive Support and Quick Response by a Expert Team

Rather than a large-scale organization, AntiCancer Japan maintains a compact team of highly specialized professionals. This allows close communication and personalized support to each client.

After a thorough consultation with the client for their target goals and study requirements, the team fine-tunes study models and protocols accordingly.

With extensive expertise specifically in oncology, the company can provide practical, experience-based advice, which may be hard to find in general-purpose testing facilities. AntiCancer Japan serves as a collaborative partner that offers companion-style contract services, working alongside clients to find the best, tailor-made solutions beyond standard protocols.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models at AntiCancer Japan

CDX (Cell Line-Derived Xenograft) Model

The CDX model is a standard tumor model induced by transplanting human cancer cell lines subcutaneously or into organs of immunodeficient mice.

Leveraging its advanced oncology expertise, AntiCancer Japan offers a wide variety of human cancer cell lines. Researchers can select the most suitable model for each cancer type, including solid tumors and leukemia.

The CDX model offers high reproducibility in tumor growth rate and drug responsiveness and is applicable to various studies, including efficacy evaluation of anticancer drugs, combination therapies, and comparison of administration routes. They can also do real-time monitoring through luminescence and fluorescence imaging with precise quantitative evaluation of treatment.

Reference: AntiCancer Japan official website (http://www.anticancerjapan.com/research/index.html)

Case Studies of Non-Clinical Research at AntiCancer Japan

Fluorescence and Luminescence Imaging to Visualize the Effects of Cancer Drugs

AntiCancer Japan uses tumor cells that express fluorescent and luminescent proteins to visualize tumor formation and treatment effects in mice. This imaging system enables non-invasive, time-course evaluation of tumor regression and regrowth following treatment.

The technique is applicable not only to subcutaneous tumor models but also to tumors implanted in the abdominal cavity, bladder, brain, liver, lungs, bone, and other organs, allowing dynamic observation across various cancer types.

Reference: AntiCancer Japan official website (http://www.anticancerjapan.com/research/index.html)

Company Information

Address	2-23-5 Ryukakujidai, Sakae-machi, Inba-gun, Chiba, Japan
Tel	0476-77-8555
Website	http://www.anticancerjapan.com/index.html

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories official website (https://www.smccro-lab.com/jp/)

SMC Laboratories has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

labcorp
(Labcorp Drug Development)

Reference: labcorp official website (https://jp.labcorp.com/)

labcorp provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
labcorp’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult labcorp
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio

Source: PhoenixBio Official Website (https://phoenixbio.co.jp/)

PhoenixBio offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us